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To explore the mechanism underlying antileukaemia eﬀect of sodium valproate, the growth and survival of the K562 cell line
were investigated. Global proﬁles of gene expression in K562 cells exposed to sodium valproate were assessed and validated. The
diﬀerentially expressed genes identiﬁed were further used to query the connectivity map database to retrieve a ranked list of
compounds that act on the same intracellular targets as sodium valproate. A signiﬁcant increase in cell apoptosis and a change
in gene expression proﬁle were observed in valproate-exposed K562 cells. The signiﬁcant enrichment analysis of gene ontology
terms for the diﬀerentially expressed genes showed that these genes were involved in many important biological processes. Eight
diﬀerentially expressed genes involved in apoptosis were veriﬁed by quantitative real-time PCR. The connectivity map analysis
showed gene expression proﬁle in K562 cells exposed to sodium valproate was most similar to that of HDACi and PI3K inhibitors,
suggesting that sodium valproate might exert antileukaemic action by inhibiting HDAC as well as inhibiting PI3K pathway. In
conclusion, our data might provide clues to elucidate the molecular and therapeutic potential of VPA in leukaemia treatment, and
the connectivity map is a useful tool for exploring the molecular mechanism of drug action.
1.Introduction
Sodium valproate (VPA) is a well-known antiepileptic drug,
alsousedtotreatbipolardisorder,migraine,andneuropathic
pain. Recently, VPA has been described as an HDAC
inhibitor, resulting in an increased interest for its use in
cancer therapy. Studies show that VPA, alone or in com-
bination with other antileukaemic compounds, possesses
signiﬁcant antileukaemic actions on acute myeloid leukemia
(AML) cells [1], chronic myeloid leukaemia (CML) cells [2–
4],acutelymphoblasticleukemia(ALL)cells[5],andchronic
lymphocytic leukemia (CLL) cells [6, 7]. Clinical trials
show that VPA therapy is of clinical beneﬁt in patients
with acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) [8–11]. However, the exact molecular
mechanisms of VPA action on leukemia treatment remain
poorly understood.
Microarray is a high-throughput tool which allows for
the analysis of global gene expression proﬁle in a single
experiment and has been widely used for exploring mo-
lecular mechanisms of pathogenesis and drug treatment.
Based on this high-throughput technology, the molecular
mechanisms underlying the observed antileukaemic activ-
ity of VPA in CLL cells [12] and AML cells [13, 14]2 Journal of Biomedicine and Biotechnology
have been described. So far, however, there has been no
study exploring genomewide gene expression changes in
CML.
The Connectivity Map (CMAP) is a collection of
genomewide transcriptional expression data from cultured
human cells treated with bioactive small molecules. It
connects drugs, genes, and diseases together through the
transitory feature of common gene-expression changes. By
comparing gene-expression signatures, this tool can be used
to ﬁnd connections among small molecules drugs aﬀecting
common molecular pathways and putative mechanisms
of action of unknown drugs. CMAP has previously been
used to discover the mechanisms of drug action [15–18]
and disease pathogenesis [19]. In the current study, we
ﬁrst investigated eﬀects of VPA on apoptosis and gene
expression proﬁles of K562 cells, a model for CML, and
then mined the CMAP database to explore the molecular
mechanism underlying the observed anti-CML eﬀect of
VPA.
2.Methods and Materials
2.1. Culture of K562 Cell Line. K562 cells, human chronic
myelogenic leukemic cell line, were procured from Sun Yat-
sen University Cancer Center. The cells were grown in RPMI
(LifeTechnologyCorporation,Camarillo,CA,USA),supple-
mented with 15% fetal bovine serum, 100U/mL penicillin,
and 1mg/mL streptomycin. Cultures were incubated at 37◦C
in 5% CO2.
2.2. Assessment of Apoptosis by Annexin V/PI Dual Staining
Method. I no r d e rt od e t e r m i n et h ee ﬀect of VPA treatment
on apoptosis rate of K562 cells, FACS analysis was carried
out as previously described [20].
2.3. Analysis of Gene Expression Proﬁle. To analyze gene
expression proﬁle, K562 cells were ﬁrst cultured for 12 hours
with 2mM VPA or without VPA as a control. Then, the
K562 cells were harvested and total RNA was extracted
using the RNeasy Mini Kit (QIAGen, USA) according to the
manufacturer’s instructions. Total RNA quality was evalu-
ated using formaldehyde agarose gel electrophoresis and was
quantiﬁed via spectrophotometry (Nanodrop, Wilmington,
DE).RNAwasampliﬁedandlabelledaccordingtoaprevious
protocol [21]. Brieﬂy, 100ng of total RNA was used to
synthesize the double-strand cDNA. RNA was ampliﬁed by
in vitro transcription using Ambion’s MessageAmp II aRNA
Ampliﬁcation Kits (Life Technologies, Austin, TX, USA).
Then, aRNA was reverse-transcribed into cDNA and further
labelled with Klenow enzyme. cDNA from VPA-pretreated
K562 cells was labelled with Cy3-deoxycytidine triphosphate
and cDNA from control K562 cells was labelled with Cy5-
deoxycytidine triphosphate. Fluorescent dye-labelled cDNA
was hybridised to an Agilent SurePrint G3 Human GE 8 ×
60K Microarray. Hybridisation, scanning, and washing were
carried out on Agilent’s Microarray Platform according to
Agilent’s standard protocols. The array data were extracted
with Agilent Feature Extraction software. After global mean
normalization, probes with an intensity <400 were ﬁltered
out for further analysis. Diﬀerentially expressed genes were
further analysed based on a signiﬁcant enrichment of GO
terms using hypergeometric distribution in the R language
package software.
2.4. Validation of Diﬀerentially Expressed Genes. To explore
the mechanism of the observed VPA-inducing apoptosis,
eight diﬀerentially expressed genes involved in apoptosis
were selected for validation of the microarray results by
quantitative real-time PCR (qRT-PCR). Total RNAs were
ﬁrst separated from K562 cell line treated with or without
VPA. The isolated total RNAs were treated with DNase and
exclusively used for validation of the microarray results.
Following DNase treatment, 1μg of DNase-treated RNA was
reverse-transcribed cDNA with oligo (dT)15 using M-MLV
reverse transcriptase (Life Technologies) in a total volume of
20μL reaction volume. After reverse transcription reaction,
1μL of the reaction mixture was used for a qPCR program of
45 cycles consisting of melting (30s at 94◦C), annealing (30s
at 58◦C), and extension (30s at 72◦C). The 20μLr e a c t i o n
mixture contained 1 × PCR Buﬀer (Mg2+ Plus), 0.5μMo f
forward primer, 0.5μM of reverse primer (Table 1), 200μM
of each dNTP, and Eva Green Master Mix in a LightCycler
480 Real-Time PCR System (Roche Applied Science). Data
were analysed by the 2−ΔΔCt method [22]. Glyceraldehyde 3-
phosphate dehydrogenase (GADPH) was used as a reference
gene. All other results were shown as fold change relative to
GADPH control.
2.5. Statistics. The microarray data have been deposited
in NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm
.nih.gov/geo/) and are accessible through GEO series
accession number GSE32189. The signiﬁcance between
groups was analyzed by the Student’s t-test (Microsoft
Excel, Microsoft Corporation, Seattle, WA). A P value of
less than 0.05 (P<0.05) was considered statistically
signiﬁcant.
2.6. Comparison of Gene Expression Proﬁles with the CMAP
Database. To further explore the mechanisms underlying
the observed eﬀects of VPA, the gene expression proﬁle
of VPA treatments was used to query the CMAP database
(build 02), which contains more than 7,000 expression
proﬁles representing 1,309 compounds [23]. The similarity
between the gene expression proﬁles of the query signature
and a CMAP instance is measured by the connectivity
score, ranging from −1 to 1. A high positive connectivity
score indicates inducement of the expression of the query
signature by the corresponding drug, a high negative,
inhibition. Prior to the query in the CMAP database via the
Internet (http://www.broad.mit.edu/cmap/), the probe ID of
Agilent SurePrint G3 Human GE 8 × 60K Microarray was
transformed into the probe ID deﬁned by the Aﬀymetrix
GeneChip Human Genome U133A array according to the
probe corresponding gene.Journal of Biomedicine and Biotechnology 3
Table 1: Primer pairs for qRT-PCR validation of diﬀerentially expressed genes involved in apoptosis.
Gene symbol GenBank Accession Primer (5  →3 )
GSN NM 198252 F CGAAGAGGTTCCTGGTGAGC
R GCTGGGTCCGTCTCGATGTA
TP53INP1 NM 033285 F CTTCTCATTGAACATCCCAGCA
R TGGGTTGTTCCAGAAAAGTTGTA
TNFSF9 NM 003811 F GAGCTTTCGCCCGACGAT
R GCTCCTTCGTGTCCTCTTTGTAG
DDIT4 NM 019058 F CCGAACTCCCACCCCAGA
R GCAACGACACCCCATCCA
POLR2G NM 002696 F AAGATTGTGGGGACCCGTGT
R GGATGAGTTGCCTTCCTTGC
LGALS1 NM 033101 F CAACCCTCGCTTCAACGC
R GGCGGTTGGGGAACTTGA
BBC3 NM 014417 F CGGACGACCTCAACGCAC
R GCACCTAATTGGGCTCCATCT
FOXO3 NM 001455 F GGGGAACTTCACTGGTGCTAA
R AACGGTATCACTGTCCACTTGC
PUF60 NM 014281 F CTGTTTCCCGAGTCAGAGCG
R CTCCTCTGTCACCTCCCCTTC
RRAGA NM 006570 F TGGTCATGTCAGATCCGTCG
R AAGGCAATTCAGCATTTTCAGA
3. Results
3.1. Analysis of Apoptosis Using the Annexin V/PI Dual Stain-
ing Method. Using the Annexin V/PI dual staining method
just as we previously reported, we measured apoptosis rate
of K562 cells. In this study the similar increase in apoptosis
was also observed in K562 cells exposed to 2mM VPA for 48
hours (11.47 ±0.25; P<0.05, n = 3), compared to the K562
control (4.77 ±0.40) [20].
3.2. Diﬀerentially Expressed Genes in K562 Cells Pretreated
with VPA. Considering that the detection of diﬀerentially
expressed genes is more easily in cells during the primary
response phase of a drug exposure at certain doses that
result in a 10–20% decrease in cell viability, we pretreated
K562 cells with 2mM VPA for 12 hours. This treatment
resulted in an approximately 12% decrease in cell viability.
The transcription proﬁles of K562 cells pretreated with or
without VPA were analyzed using Agilent gene expression
microarray. A total of 706 transcripts were identiﬁed as
being signiﬁcantly diﬀerentially expressed. The signiﬁcant
enrichment analysis of GO terms for the diﬀerentially
expressed genes using the R language software package
showed that apoptosis was the mostly enrichment function
genes, and 34 genes involved in apoptosis were listed in
Table 2.
3.3. Validation of the Diﬀerentially Expressed Genes Using
qRT-PCR. Based on the microarray results, eight diﬀeren-
tially expressed genes involved in apoptosis were selected for
qRT-PCR conﬁrmation. Consistent with the results obtained
from microarray analysis, PERP, GSN, TP53INP1, NXA4,
FI6, ERPINB9, and CDKN2D were upregulated and NFKB1
was downregulated (Figure 1).
3.4. Comparison of Gene Expression Proﬁles with the CMAP
Database. To gain a better understanding of the anticancer
and proapoptotic mechanisms of VPA exposure in a CML
model, the gene expression proﬁle of diﬀerentially expressed
genes related to VPA treatment was used to compare with
those of 1,309 compounds in the CMAP database [23,
24]. The similarity of the gene expression proﬁle between
the query signature and a CMAP instance were measured
by the connectivity score, which ranges from −1t o1 .
Only drugs with positive connectivity scores, which induce
the expression of the query signature, are listed (Table 3).
The results showed that the top ten drug hits belong to
HDACi PI3K inhibitor, selective estrogen receptor modula-
tor,antipsychoticorantimycobacterialagent,consistentwith
VPA’s pharmaceutical actions including recently reported
action of inhibiting HDAC. Gene expression proﬁle in K562
cells exposed to VPA observed in this study was most similar
to that of HDACi and PI3K inhibitor in CMAP database.
4. Discussion
VPA is a short-chain, branched fatty acid that has recently
been described as a potent HDACi at therapeutic concentra-
tions. Unlike other HDAC inhibitors, which are associated
with various toxic side eﬀects, VPA is clinically available.
It can be taken orally, can cross the blood-brain barrier,
and can be used for extended periods. HDAC inhibition is4 Journal of Biomedicine and Biotechnology
Table 2: Diﬀerentially expressed genes involved in apoptosis detected by signiﬁcant enrichment analysis of GO terms using the R language
software package.
Genes GenBank accession Fold change Gene description
PDCD7 NM 005707 −2.20 Programmed cell death 7
RRAGA NM 006570 2.03 Ras-related GTP binding A
DAPK3 NM 001348 2.04 Death-associated protein kinase 3
PUF60 NM 014281 −2.00 Poly-U binding splicing factor 60kda isoform c
FOXO3 NM 001455 2.16 Forkhead box O3A
ARHGEF18 NM 015318 2.20 Rho/Rac guanine nucleotide exchange factor 18
BBC3 NM 014417 −2.18 BCL2 binding component 3 isoform 1
GSN NM 198252 5.02 Gelsolin isoform c
LGALS1 NM 033101 2.58 Galectin-1
NFKB1 NM 003998 −3.33 Nuclear factor kappa-B, subunit 1 isoform 1
SH3GLB1 NM 016009 2.82 SH3-containing protein SH3GLB1
POLR2G NM 002696 2.02 DNA directed RNA polymerase II polypeptide G
DDIT4 NM 019058 −2.23 Homo sapiens DNA-damage-inducible transcript 4
STEAP3 NM 182915 −2.52 Dudulin 2 isoform a
DRAM1 NM 018370 2.29 DNA-damage regulated autophagy modulator 1
RNF130 NM 018434 2.07 Ring ﬁnger protein 130 precursor
AVEN NM 020371 −2.62 Cell death regulator Aven
TRIB3 NM 021158 −2.19 Tribbles 3
BAX NM 138764 2.06 BCL2-associated X protein isoform beta
BID NM 197966 −2.76 BH3 interacting domain death agonist isoform 1
PERP NM 022121 9.42 PERP, TP53 apoptosis eﬀector
SPTAN1 NM 003127 2.63 Spectrin, alpha, nonerythrocytic 1
BUB1B NM 001211 −2.20 Budding uninhibited by benzimidazoles 1 beta
VDAC1 NM 003374 −2.37 Voltage-dependent anion channel 1
BCL2L12 NM 138639 2.19 BCL2-like 12 isoform 1
CUL1 NM 003592 −2.08 Cullin 1
YARS NM 001040436 −2.30 Tyrosyl-TRNA synthetase
TNFSF9 NM 003811 2.38 Tumor necrosis factor (ligand) superfamily
IER3 NM 003897 2.17 Immediate early response 3
ARHGEF2 NM 004723 −2.10 Rho/Rac guanine nucleotide exchange factor 2
TP53INP1 NM 033285 3.03 Tumor protein p53 inducible nuclear protein 1
ITM2B NM 021999 2.32 Integral membrane protein 2B
LITAF NM 004862 2.25 Lipopolysaccharide-induced TNF-alpha factor
ESPL1 NM 012291 −2.11 Separase
−: indicate downregulation.
responsible for the acetylation of histones and nonhistone
proteins such as hsp90 [25] and p53 [26]. This event has
been associated with the induction of apoptosis in many
models of leukaemia [27, 28]. Thus, the use of VPA prior
to or concurrently with anticancer drugs may prove to be a
beneﬁcial treatment of leukaemia [8, 29]. The K562 cell line,
originating from a patient diagnosed with CML in terminal
blast crisis, is highly undiﬀerentiated and of the granulocytic
series.Inthiscurrentstudy,weinvestigatedtheapoptosisrate
of K562 cells exposed to VPA. The observed apoptosis result
was in agreement with our previous reports [20].
Although the molecular mechanisms underlying antileu-
kaemicactivityofVPAinCLL[12]andAML[13,14]models
have been reported, genomewide gene expression changes
in CML, however, have not been described. CML is a type
of myeloproliferative disease associated with a characteristic
chromosomal translocation called the Philadelphia chromo-
some. Conversely, CLL aﬀects B-cell lymphocytes, and AML
is characterized by the rapid growth of abnormal white
blood cellsthataccumulateinthebonemarrow andinterfere
with the production of normal blood cells. The observed
clinical features and pathology of CML patients, as well as
the therapy options, are quite diﬀerent from those of CLL
andAMLpatients.Consequently,theeﬀectofVPAtreatment
on CML patients and the underlying molecular mechanisms
may be diﬀerent from eﬀects observed in CLL and AMLJournal of Biomedicine and Biotechnology 5
Table 3: Top CMAP hits correlated with gene expression signature induced by VPA.
Rank CMAP drug P Mean score Enrichment Speciﬁcity Percent
nonnull Function
1 Vorinostat 0.00000 0.918 0.974 0.0201 100 HDACi
2 Trichostatin A 0.00000 0.817 0.957 0.0000 96 HDACi
3 Wortmannin 0.00000 0.335 0.695 0.0065 77 PI3K inhibitor
4 Ly-294002 0.00000 0.325 0.564 0.0201 65 PI3K inhibitor
5 VPA 0.00000 0.370 0.516 0.0000 61 Anti-epileptic; HDACi;
Mood stabilizer
6 Raloxifene 0.00002 0.302 0.789 0.0000 85 SERM
7 Triﬂuoperazine 0.00002 0.303 0.594 0.1154 68 Antipsychotic
8 Scriptaid 0.00004 0.728 0.968 0.0185 100 HDACi
9 Rifabutin 0.00004 0.802 0.967 0.0052 100 Antimycobacterial agent
10 Thioridazine 0.00008 0.260 0.486 0.2831 65 Antipsychotic
The connectivity score, similarity measurement of the gene expression proﬁle between the query signature and that of a CMAP instance, ranges from −1t o
1. Only drugs with positive connectivity scores, which induce the expression of the query signature, are listed. HDACi: histone deacetylase inhibitor. SERM:
selective estrogen receptor modulator. VPA: valproic acid.
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Figure 1: Alterations in the expression levels identiﬁed by microar-
ray were conﬁrmed using qRT-PCR. Fold changes between K562
cell line treated with and without valproate detected by microarray
were compared with those measured by qRT-PCR. In qRT-PCR
assay, RNA was isolated from K562 cell line treated with or without
valproate exclusively for validation of diﬀerentially expressed genes.
mRNA levels were normalized with GADPH and fold changes
were calculated by dividing mRNA level of each K563 cell line
treatedwithvalproatebymeanmRNAlevelfromcontrolsamplesin
triplicate. Data are mean values ± standard deviations of the means
from three independent experiments performed in triplicate.
patients. Based on this information, we investigated the
global gene expression proﬁle of K562 cells exposed to
VPA using gene expression microarray. Our microarray data
demonstrated that VPA exposure resulted in widespread
gene expression changes in this cell line. The signiﬁcant
enrichmentanalysisofGOtermsrevealedthatgenesinvolved
in apoptosis were signiﬁcantly altered by VPA treatment.
This alteration was in accordance with the increase in cell
a p o p t o s i so b s e r v e di nV P A - p r e t r e a t e dK 5 6 2c e l l su s i n gﬂ o w
cytometry.
To gain a better understanding of the antileukaemic
mechanisms of VPA exposure in a CML model, the gene
expression proﬁle of diﬀerentially expressed genes related
to VPA treatment was utilised to compare with those of
1,309 compounds in the CMAP database. CMAP analysis
showed that the top ten drug hits included HDACi, PI3K
inhibitor and VPA itself. These results were consistent with
VPA’s pharmaceutical actions including recently reported
action of inhibiting HDAC, indicating the reliability of our
result of gene expression proﬁle. In this study, VPA ranked
in the top ﬁve drug hits. This result not only reﬂects the
reliability of our result of gene expression proﬁle, but also
indicates that the connectivity map is a reliable tool for
exploring molecularmechanismofdrugaction.Thetopfour
drug hits were vorinostat (suberoylanilide hydroxamic acid,
ZolinzaTM), trichostatin A, Wortmannin, and LY-294002.
Vorinostat and trichostatin A belong to HDACi. HDACi has
am u l t i t u d eo fe ﬀects on cancer cells. It can induce cell-
cycle arrest, promote diﬀerentiation, and stimulate tumor
cell death [30]. Itactivatesthe apoptosis of cancercellsby the
death-receptor(extrinsic)pathwayand/orthemitochondrial
(intrinsic) pathway [31]. The latter is induced by stress
stimuli that disrupt the mitochondrial membrane. Recent
studieshaveshowedthatHDACitreatmentgeneratesreactive
oxygen species (ROS) and causes DNA damage in AML
cell line, AML patient-derived blasts cultured ex vivo [32],
and CML cell line [33], suggesting that ROS inducing
intrinsic apoptosis might be one of important mechanisms
underlying pro-apoptotic eﬀect of HDACi. The intrinsic
apoptosismaybedependentorindependentonp53pathway.
We found that expressions of many genes involved in p53-
dependent apoptotic pathway were up-regulated by VPA, for
example, TP53INP1, PERP, and BAX (Table 2). TP53INP16 Journal of Biomedicine and Biotechnology
promotes p53/TP53 phosphorylation in response to double-
strand DNA breaks. PERP plays a role as an eﬀector in the
TP53-dependent apoptotic pathway. BAX is regulated by p53
gene. It forms the mitochondrial pore leading to mitochon-
drial depolarization by oligomerization with BAK [34]a n d
confers an essential gateway for the activation of caspases
in the intrinsic apoptosis. Moreover, GO analysis showed
that the genes involved in release of cytochrome c from
mitochondria (GO: 0001836) were signiﬁcantly enriched
(P = 0.00066) (data not shown). It has been reported
that VPA produces DNA oxidative damage in liver cells
[35, 36], increases ROS formation, and induces apoptosis in
postimplantation embryos [37]. Taken together, VPA might
induce ROS and activate p53-dependent apoptosis of k562.
The expression of the BCR/ABL oncogene is the major
pathogenic event in CML and the abnormal BCR/ABL
tyrosine kinase promotes leukaemogenesis by inducing the
phosphorylation of multiple downstream protein targets
that mediate growth promoting and antiapoptotic signals,
including MAPK/ERK and PI3K pathways [38–40]. PI3K is
required only for the proliferation of BCR/ABL-dependent
leukemic cells but not of normal hematopoietic cells [41,
42]. Wortmannin and LY294002 are the earliest and still
widely employed inhibitors of PI3K. Studies have shown
they are able to block proliferation of Ph1-positive cells
[38, 43, 44] and enhance the antileukemia eﬀect of Bcr-
Abl tyrosine-kinase inhibitor [45–47], the initial choice of
treatment for most CML patients. Based on CMAP analysis,
we speculate that VPA might inhibit PI3K pathway too,
and such inhibition might be one important mechanism
by which VPA exerts antileukaemic action. We found that
one member of the forkhead transcription factor O (FOXO)
family, FOXO3, was upregulated by VPA (Table 2). FOXO
family plays an important role in stress defence and it
is negatively regulated by AKT-dependent phosphorylation
[48].
In conclusion, we observed that VPA exposure altered
mRNA expression in the K562 cell line. The CMAP analysis
suggests that these alterations might be associated with
inhibiting eﬀect of VPA on HDAC as well as PI3K pathway.
T h ed a t ao b t a i n e di nt h i ss t u d ym i g h tp r o v i d ec l u e st o
elucidate the molecular and therapeutic potential of VPA in
leukaemiatreatment,andtheCMAP,bywhichweconﬁrmed
GO analysis and analyze the possible mechanisms of VPA
antileukaemia, is a useful tool for exploring molecular
mechanisms of drug actions.
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